BackVerve Therapeutics Overview

Verve Therapeutics Long Term Debt

Verve Therapeutics's long-term debt is $58M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$58.12M
8.41% YoYΔ $-5.33M vs prior year quarter

Peer trimmed avg / median

Loading

Verve Therapeutics Long Term Debt History

Loading

Verve Therapeutics vs. peers: Long Term Debt Comparison

Loading

Verve Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Verve Therapeutics (VERV) FAQ

As of the most recent data (March 2025), VERV shows a long-term debt of $58M. That compares with $63M in the prior-year period — down 8.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VERV's long-term debt is now $58M (was $63M) — a 8.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Verve Therapeutics is outperforming or lagging.

Tracking VERV's long-term debt over time shows whether Verve Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $58M That compares with $63M in the prior-year period — down 8.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Verve Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $58M) with ownership activity and broader fundamentals.

Verve Therapeutics's long-term debt is $58M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.